These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37376118)

  • 1. Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies.
    Pon'kina DA; Kuranov SO; Marenina MK; Meshkova YV; Zhukova NA; Khvostov MV; Luzina OA; Tolstikova TG; Salakhutdinov NF
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoprotective Effect of a New FFAR1 Agonist-N-Alkylated Isobornylamine.
    Pon Kina D; Kuranov S; Khvostov M; Zhukova N; Meshkova Y; Marenina M; Luzina O; Tolstikova T; Salakhutdinov N
    Molecules; 2023 Jan; 28(1):. PubMed ID: 36615590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Evaluation of Hypoglycemic Activity of Structural Isomers of ((Benzyloxy)phenyl)propanoic Acid Bearing an Aminobornyl Moiety.
    Kuranov SO; Pon Kina DA; Meshkova YV; Marenina MK; Khvostov MV; Luzina OA; Tolstikova TG; Salakhutdinov NF
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates.
    Rady B; Liu J; Huang H; Bakaj I; Qi J; Lee SP; Martin T; Norquay L; Player M; Pocai A
    Front Endocrinol (Lausanne); 2022; 13():1061688. PubMed ID: 36482991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of free fatty acid receptor 1 improves hepatic steatosis through a p38-dependent pathway.
    Ou HY; Wu HT; Lu FH; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Mol Endocrinol; 2014 Oct; 53(2):165-74. PubMed ID: 25008074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bornyl Derivatives of
    Kuranov S; Luzina O; Khvostov M; Baev D; Kuznetsova D; Zhukova N; Vassiliev P; Kochetkov A; Tolstikova T; Salakhutdinov N
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33228030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
    Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
    Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance.
    Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S
    Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans.
    Wagner R; Kaiser G; Gerst F; Christiansen E; Due-Hansen ME; Grundmann M; Machicao F; Peter A; Kostenis E; Ulven T; Fritsche A; Häring HU; Ullrich S
    Diabetes; 2013 Jun; 62(6):2106-11. PubMed ID: 23378609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans.
    Wagner R; Hieronimus A; Lamprinou A; Heni M; Hatziagelaki E; Ullrich S; Stefan N; Staiger H; Häring HU; Fritsche A
    Mol Metab; 2014 Sep; 3(6):676-80. PubMed ID: 25161890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators.
    Teng D; Zhou Y; Tang Y; Liu G; Tu Y
    J Chem Inf Model; 2022 Aug; 62(15):3664-3675. PubMed ID: 35877470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution.
    Yoshioka K; Yamashita H; Shimizu K; Shimomura S; Shibata T; Miyazaki JI; Honda H
    Biochem Biophys Res Commun; 2021 Apr; 550():177-183. PubMed ID: 33706101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1.
    Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H
    Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.